Physician profile
Janel E Duval
NPI 1790318079
$2,802.74
in general payments reported to CMS, 2019-2025
25 companies · $280 in 2025
The $280 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $429 · 2022: $914 · 2023: $646 · 2024: $534 · 2025: $280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,459.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $513.73 | 2022 | |
| Abbvie INC. | $457.81 | 2021-2025 | |
| Novo Nordisk INC | $403.41 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $226.81 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $188.64 | 2021-2025 | Farxiga, Airsupra |
| Biohaven Pharmaceutical Holding Company Ltd. | $157.09 | 2022 | |
| Pfizer INC. | $146.49 | 2023-2024 | |
| Glaxosmithkline, LLC. | $143.87 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Currax Pharmaceuticals LLC | $67.57 | 2021-2023 | Contrave |
| Amgen INC. | $64.22 | 2024 | Repatha, Otezla |
| Phathom Pharmaceuticals, INC. | $63.34 | 2024 | Voquezna |
| Astellas Pharma US INC | $60.81 | 2022-2025 | Veozah |
| Exact Sciences Corporation | $47.17 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.98 | 2022-2024 | |
| Dexcom, INC. | $38.46 | 2023-2024 | Dexcom G6 Transmitter |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.22 | 2024-2025 | Xifaxan |
| Inspire Medical Systems, INC. | $26.51 | 2024 | Inspire |
| Abbott Laboratories | $20.66 | 2025 | Freestyle Libre |
| Genentech USA, INC. | $20.62 | 2021 | |
| Sumitomo Pharma America, INC. | $16.53 | 2024 | Gemtesa |
| Medtronic, INC. | $14.88 | 2024 | Intellis Adaptivestim |
| Aimmune Therapeutics, INC. | $14.07 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.52 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.28 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $11.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janel Duval listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.